A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois +2 locations
Conditions: Non-Small Cell Lung Cancer
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois
Conditions: Lung Cancer
Phase II Study in Patients With Operable Breast Cancer
Unknown
The study will evaluate the safety and efficacy of the combination PLD, paclitaxel, and trastuzumab in patients with operable breast cancer. Patients will be treated with the combination for 18 weeks, followed by surgery.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
01/14/2010
Locations: John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
Conditions: Breast Cancer
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Hematology Oncology Associates of Illinois, Chicago, Illinois +2 locations
Conditions: Carcinoma, Non-Small-Cell Lung
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Completed
This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2008
Locations: University of Chicago, Chicago, Illinois +2 locations
Conditions: Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Conditions: Colorectal Cancer